Wockhardt Limited

Informe acción NSEI:WOCKPHARMA

Capitalización de mercado: ₹200.4b

Salud financiera de hoja de balance de Wockhardt

Salud financiera controles de criterios 4/6

Wockhardt tiene un patrimonio de accionistas total de ₹37.1B y una deuda total de ₹21.5B, lo que sitúa su ratio deuda-patrimonio en 58%. Sus activos y pasivos totales son ₹75.9B y ₹38.8B respectivamente. El BAIT de Wockhardt es de ₹1.1B, por lo que su ratio de cobertura de intereses es de 0.4. Tiene efectivo e inversiones a corto plazo que ascienden a ₹2.2B.

Información clave

58.0%

Ratio deuda-patrimonio

₹21.54b

Deuda

Ratio de cobertura de intereses0.4x
Efectivo₹2.23b
Patrimonio₹37.13b
Total pasivo₹38.75b
Activos totales₹75.88b

Actualizaciones recientes sobre salud financiera

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 02
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Aug 20
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jul 27
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 30
Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Jun 22
Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Feb 21
Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

Dec 19
There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Oct 14
There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Jun 23
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Feb 18
Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jan 04
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Jul 26
Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

May 18
Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Jan 26
Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Dec 01
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₹20.1B) de WOCKPHARMA no cubren sus pasivos a corto plazo (₹23.8B).

Pasivo a largo plazo: Los activos a corto plazo de WOCKPHARMA (₹20.1B) superan a sus pasivos a largo plazo (₹15.0B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de WOCKPHARMA (52%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de WOCKPHARMA ha pasado de 77.2% a 58% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: WOCKPHARMA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: WOCKPHARMA dispone de suficiente cash runway para 1.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 23.5% cada año.


Descubre empresas con salud financiera